Serum folate receptor α (sFR) in ovarian cancer diagnosis and surveillance

Novelty and Impact Statement: Our findings suggest that soluble folate receptor (sFR) could be used in both the initial diagnosis and surveillance of patients with ovarian cancer. Our cohort constitutes one of the largest comparison groups for sFR analyzed so far. We have defined the background leve...

Full description

Saved in:
Bibliographic Details
Published in:Cancer medicine (Malden, MA) MA), 2019-03, Vol.8 (3), p.920-927
Main Authors: Farran, Batoul, Albayrak, Samet, Abrams, Judith, Tainsky, Michael A., Levin, Nancy K., Morris, Robert, Matherly, Larry H., Ratnam, Manohar, Winer, Ira
Format: Article
Language:English
Subjects:
Acids
Biomarkers
Biomarkers, Tumor - blood
CA-125 Antigen - blood
Cancer therapies
Carcinoma, Ovarian Epithelial - blood
Carcinoma, Ovarian Epithelial - diagnosis
Case-Control Studies
Chemotherapy
Clinical Cancer Research
Diagnosis
Disease Progression
Female
Folate Receptor 1 - blood
Folic acid
gynecologic oncology
Humans
Medical prognosis
Medical research
Membrane Proteins - blood
Middle Aged
Neoplasm Staging
Original Research
Ovarian cancer
Patients
Prognosis
Prospective Studies
Proteins
Studies
Surveillance
translational research
Tumor markers
Vitamin B
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Novelty and Impact Statement: Our findings suggest that soluble folate receptor (sFR) could be used in both the initial diagnosis and surveillance of patients with ovarian cancer. Our cohort constitutes one of the largest comparison groups for sFR analyzed so far. We have defined the background level of sFR using healthy volunteers. This is also the first study to prospectively follow patients in the surveillance setting to concurrently identify differential changes in tumor markers CA‐125 and sFR. Collectively, our data demonstrate that sFR could improve diagnostic accuracy. Additionally, the monitoring of sFR and CA125 (and potentially other markers) could conceivably improve cancer surveillance, affecting prognosis. We have initiated a prospective clinical trial studying sFR induction in the initial diagnosis and surveillance of OVCA as a means to abrogate potential limitations of this biomarker.
ISSN:2045-7634
2045-7634
DOI:10.1002/cam4.1944